New acoustic detection technology intended to rule out coronary artery disease has shown better than 90 percent accuracy in diagnosing patients who do not have CAD.
Two companies—one in the United States and one in Denmark—recently concluded trials which demonstrated their technologies’ accuracy and expect to begin marketing their products within months.
“We’re calling ourselves the radically more powerful stethoscope,” Marie Johnson, founder and CEO of Northfield, MN-based Aum Cardiovascular, said. Aum (pronounced “ohm”) developed the CADence System, which uses a handheld acoustic device, a Bluetooth-equipped tablet, and cloud connectivity to test for and analyze telltale turbulence undetectable by human ears in blood flow through the coronary arteries.
